Detecting bcl-b expression in cancer and uses thereof
AssigneeBurnham Institute for Medical Research
InventorsJohn C. Reed, Maryla Krajewska
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods of detecting Bcl-B expression in cancer cells to prognose, monitor, or select therapies for cancers such as breast cancer, prostate cancer, lung cancer, or gastric cancer.
Claims18
A method of determining the severity of a breast cancer, prostate cancer, or lung cancer, comprising examining the expression of Bcl-B in one or more cells of said cancer, wherein an increase in the amount of Bcl-B expression in the cancer cells or an increase in the number or percentage of cells with detectable Bcl-B expression as compared to that of normal reference cells indicates an increase in cancer severity.
A method of determining the severity of a gastric cancer, comprising examining the expression of Bcl-B in one or more cells of said gastric cancer, wherein a decrease in the amount of Bcl-B expression in the cancer cells or a decline in the number or percentage of cells with detectable Bcl-B expression as compared to that of normal reference cells indicates an increase in cancer severity.
A method of monitoring the progression of a breast cancer, prostate cancer, or lung cancer, comprising examining the expression of Bcl-B in one or more cells of said cancer, wherein an increase in the amount of Bcl-B expression in the cancer cells or an increase in the number or percentage of cells with detectable Bcl-B expression as compared to that of normal reference cells indicates an increased risk of cancer progression.
A method of monitoring the progression of a gastric cancer, comprising examining the expression of Bcl-B in one or more cells of said cancer, wherein a decrease in the amount of Bcl-B expression in the cancer cells or a decrease in the number or percentage of cells with detectable Bcl-B expression as compared to that of normal reference cells indicates an increased risk of cancer progression.
A method of selecting a therapy for treating a subject with breast cancer or prostate cancer, comprising examining the expression of Bcl-B in one or more cells of said cancer, wherein a higher amount of Bcl-B expression in the cancer cells or a higher number or percentage of cancer cells with detectable Bcl-B expression as compared to that of non-metastatic reference cells indicates that the selected treatment is adjuvant chemotherapy or hormonal therapy, wherein a lower or equivalent amount of Bcl-B expression in the cancer cells or a lower or equivalent number or percentage of cancer cells with detectable Bcl-B expression as compared to that of non-metastatic reference cells indicates that the selected treatment is surgery, local therapy, or a combination thereof.
A method of selecting a therapy for treating a subject with lung cancer, comprising examining the expression of Bcl-B in one or more cells of said cancer, wherein a higher amount of Bcl-B expression in the cancer cells or a higher number or percentage of cancer cells with detectable Bcl-B expression as compared to that of non-metastatic reference cells indicates that the selected treatment is aggressive chemotherapy, investigational drugs, or a combination thereof.
Dependencies are inferred from the claim text.